KalVista Q3 2022 Earnings Report

KalVista reported third fiscal quarter results with KVD900 Phase 3 KONFIDENT trial initiated and KVD824 Phase 2 KOMPLETE clinical trial enrollment on track.

Key Takeaways

KalVista Pharmaceuticals reported no revenue for the third fiscal quarter ended January 31, 2022. The net loss was $22.5 million, or $(0.92) per share. Research and development expenses were $19.7 million, and general and administrative expenses were $6.9 million. Cash, cash equivalents, and marketable securities totaled $194.8 million as of January 31, 2022.

Initiated the Phase 3 clinical trial of KVD900 (KONFIDENT) for on-demand treatment of HAE attacks.

Continued enrollment in the Phase 2 clinical trial of KVD824 (KOMPLETE) for HAE prophylaxis, with data expected in mid-2023.

Presented data for KVD900 at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting.

Made continued progress in the Factor XIIa inhibitor program, with an expected first IND for an oral Factor XIIa inhibitor candidate in 2023.

EPS

-$0.92

Previous year: -$0.56

+64.3%

Cash and Equivalents

$45.6M

Previous year: $17.7M

+157.1%